Non-Small-Cell Lung Cancer | Current Treatment: Physician Insights | US | 2018
The treatment landscape for NSCLC continues to evolve at a rapid pace with the additions of new therapies and label expansions of current therapies into new patient populations. Examples include the approvals of Alunbrig for ALK-positive metastatic NSCLC,Tafinlar plus Mekinist for BRAF-mutation-positive NSCLC, and Imfinzi for unresectable stage III NSCLC as well as the label expansion of Keytruda in combination with chemotherapy as a first-line regimen for metastatic nonsquamous patients. Our primary research provides insight into the current use of approved therapies for NSCLC in the United States and uncovers key factors that influence medical oncologists’ prescribing decisions in this highly dynamic indication.
Related Market Assessment Reports
Report
Venous Thromboembolism – Current Treatment – Treatment Algorithms: Claims Data Analysis – Venous Thromboembolism (US)
Venous thromboembolism (VTE) is the obstruction of a vein caused by a thrombus, described as deep vein thrombosis (DVT) or pulmonary embolism (PE), depending on the vein affected. Anticoagulants…
Report
Attention-Deficit-Hyperactivity Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult ADHD (US)
Attention-deficit / hyperactivity disorder (ADHD), a common childhood neurodevelopmental condition that can persist into adulthood, affects about 6% of U.S. adults, or approximately 15.5 million…
